Proposal to list beds and mattresses supplied by Permobil New Zealand Limited

Hospital devices Consultation Closed

PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule.

What we’re proposing

PHARMAC is seeking feedback on a proposal to list beds and mattresses supplied by Permobil New Zealand Limited (“Permobil”) in Part III of Section H of the Pharmaceutical Schedule from 1 July 2021.

Consultation closes at 4pm Thursday 3 June 2021 and feedback can be emailed to

What would the effect be?

From 1 July 2021 the beds and mattresses supplied by Permobil would be listed under a proposed national agreement for all DHB hospitals to purchase under, subject to consultation and approval by PHARMAC’s board or delegate (“Agreement”).

The Agreement would not be for sole supply and DHBs can continue to purchase other suppliers’ brands of beds and mattresses.

The Agreement would supersede any existing DHB agreements with Permobil for the medical devices included in the Agreement. Any medical device listed in the Agreement and purchased by a DHB would be in accordance with the terms and conditions, including price, stated in the Agreement effective from the date of listing in the Pharmaceutical Schedule.

As part of the Agreement Permobil would provide appropriate training and education services that would be tailored to the individual needs of DHBs, in formats and at times as required by DHBs.

Pricing for the medical devices in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by PHARMAC.

Who we think will be interested

  • Suppliers and wholesalers
  • DHB staff
    • Clinical engineers, maintenance services and facilities staff
    • Clinical staff across all areas of hospitals
    • Clinical support staff
    • DHB procurement and supply chain
    • DHB loan store staff

About the medical devices

Beds and mattresses

Hospital beds and mattresses are specially designed for hospitalised patients or others in need of some form of health care. These beds and mattresses have special features both for the comfort and well-being of the patient and for the convenience of health care workers.

Why we’re proposing this

In September 2020 PHARMAC issued a Registration of Interest (“ROI”) for ranges of medical devices, including beds and mattresses, considered for listing on the Pharmaceutical Schedule.

The ROI was undertaken to transfer the responsibility for management of beds and mattresses from New Zealand Health Partnerships to PHARMAC. The ROI was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

PHARMAC has been working with suppliers who responded to the ROI to seek provisional agreements. As Permobil does not currently have an agreement in place with NZHP for the supply of beds and mattresses PHARMAC is seeking feedback on the proposal to list beds and mattresses supplied by Permobil. This proposal is the latest to arise from the ROI process.

Details about our proposal

The proposal would result in listing 55 medical devices for purchase and rental in the Pharmaceutical Schedule covering the following brands:

  • Aspire
  • Big Ted
  • Botero
  • Deutscher
  • Modular Therapy
  • Permobil
  • Rose
  • Talley
  • Walmsley

Further information, including pricing and contractual details, has been provided to DHB Procurement personnel. Clinicians interested in further detail on what this change means for their DHB should engage with their Procurement teams.

To provide feedback

Send us an email: by 4pm Thursday 3 June 2021.

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Your feedback may be shared

Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.

We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.